NeuroPace, Inc. (NPCE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for NeuroPace, Inc. due to higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - NeuroPace is expected to report a quarterly loss of $0.14 per share, reflecting a year-over-year change of +22.2% [3]. - Revenues are projected to be $25.95 million, which is an increase of 20.9% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 15.25% lower in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for NeuroPace aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12]. Earnings Surprise Prediction - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. - NeuroPace currently holds a Zacks Rank of 4, making it challenging to predict an earnings beat [12]. Historical Performance - In the last reported quarter, NeuroPace was expected to post a loss of $0.20 per share but actually reported a loss of -$0.11, resulting in a surprise of +45.00% [13]. - Over the past four quarters, NeuroPace has beaten consensus EPS estimates three times [14]. Industry Comparison - Teleflex, another company in the Zacks Medical - Instruments industry, is expected to report an EPS of $3.73 for the same quarter, indicating a year-over-year change of -4.1% [18]. - Teleflex's revenues are expected to be $925.96 million, up 16.4% from the previous year, but it has a negative Earnings ESP of -2.70% [19][20].